HRCM
ANIP icon

Hawk Ridge Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Hawk Ridge Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-196,661
Closed -$8.01M – 43
2020
Q1 		$8.01M Buy
196,661
+7,900
+4% +$420K 1.35% 24
2019
Q4 		$11.6M Buy
188,761
+33,800
+22% +$2.24M 1.89% 23
2019
Q3 		$11.3M Buy
154,961
+31,400
+25% +$2.35M 2.26% 16
2019
Q2 		$10.2M Hold
123,561
– – 1.88% 23
2019
Q1 		$8.72M Buy
+123,561
New +$7.27M 1.84% 25

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hawk Ridge Capital Management's ANIP Position: Q2 2020 in Review

Hawk Ridge Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2020, closing a stake of 196,661 shares — an estimated $8.01M sold.

Hawk Ridge Capital Management first reported a position in ANIP in Q1 2019 and held it in 5 quarters. The position peaked at $11.6M in Q4 2019. 134 funds tracked by Wall St. Rank hold ANIP as of Q2 2020.

  • Hawk Ridge Capital Management reported no remaining ANI Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Hawk Ridge Capital Management sold 196,661 ANI Pharmaceuticals shares in Q2 2020, an estimated $8.01M.
  • Hawk Ridge Capital Management first reported a position in ANI Pharmaceuticals in Q1 2019 and held it in 5 quarters.
  • Hawk Ridge Capital Management's ANI Pharmaceuticals position peaked at $11.6M in Q4 2019.
  • 134 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2020.

Based on Hawk Ridge Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.